Vacunas Personalizadas Contra el Cáncer de ARNm : Moderna y Merck & Co Versus BioNTech y Roche .

 

Personalised mRNA Cáncer Vaccines : Moderna And Merck & Co Versus BioNTech And Roche .

 

While  Messenger ribonucleic acid (mRNA)-based cancer vaccines have been in development for decades, their development had languished. However, for Pfizer, BioNTech, and Moderna, their experience in this vaccine technology led to the rapid availability of mRNA vaccines for Covid-19, and now interest in mRNA cancer vaccines has been decidedly revived .

Akin to the Covid-19 mRNA vaccines, which work by containing an mRNA sequence corresponding to the presented spike proteins on the surface of SARS-CoV-2, mRNA cancer vaccines introduce a sequence of mRNA corresponding to an antigen expressed by a tumour cell, thereby stimulating an immune response to recognise and destroy cancerous cells expressing those antigens .

Cancer vaccines are classed as either universal, where they are given to all patients of a particular population with a tumour type, or personalised, where the patient’s tumour is profiled to find the best antigen match . ...